Mesoblast's Australian shares climb as O'Brien becomes finance chief of US division

ASX-listed shares of inflammatory disease drug-maker Mesoblast MSB.AX rise as much 3.6% to A$2.3, snapping two sessions of consecutive losses

Co appoints James O'Brien as its U.S.-based CFO

Says Jim's recent CFO roles included NASDAQ-listed biopharmaceutical company Cognition Therapeutics Inc CGTX.O, overseeing successful initial public offering, among others

Stock is fourth-biggest percentage gainer in the benchmark S&P/ASX 200 index .AXJO

Stock up 2.7% at A$2.28, as at 0104 GMT

Stock down 26.5% this year, including the day's move